Post-market Clinical Follow-up (PMCF) Study of Safety and Performance of 502-01 AnGelHA 2

Recruiting now

Conditions studied: Wrinkles

In brief

Post-market clinical follow-up (PMCF) investigation to evaluate the performance and safety of AnGelHA 2 filler for the correction of moderate to severe wrinkles and folds and facial contour remodeling, in a routine clinical setting.

Key facts

Study ID

NCT07495865

Run by

Glyance

People needed

87

Starts

2026-02-08

Expected to finish

2027-03-12

Last updated by the study team

2026-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men or women of any race, 18 years of age or older.
• Able to read, understand and sign informed consent.

You may not qualify if…

• Pregnant or lactating women (contraindications as per IFU).
• Having received prior dermal filler injections in the six months preceding the study.
• Previously treated with semi-permanent or permanent filler in the intended injection area.
• Presenting with a cutaneous disorder, inflammation or infection near to the treatment area.
• Known hypersensitivity to lidocaine and/or lidocaine HCl or hyaluronic acid.
• Metabolic or endocrine uncontrolled disease, anaphylaxis, severe allergies or uncontrolled immune disorder.
• Undergoing or planning to undergo peeling treatment or laser-/ultrasound-based treatment within 3 weeks before or after injection.
• Have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs such as aspirin, ibuprofen), or other substances known to prolong time of coagulation from a week before treatment. A wash-out period of a week is allowed.
• Subject, who has a condition or is in Fuse

Where it is running

• Glyance Ltd — Lod, Israel, Israel (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.